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Abstract
Background: DNA vaccines have emerged as an attractive approach for the generation of cytotoxic T lymphocytes
(CTL). In our previous study, we found That Toll like receptor (TLR) ligands are promising candidates for the development
of novel adjuvants for DNA vaccine. To improve the efficacy of DNA vaccine directed against human papillomavirus (HPV)
tumors, we evaluated whether co-administration of a TLR4 ligand, monophosphoryl lipid A (MPL), and Natural Killer T Cell
Ligand α-Galactosylceramide(α-GalCer) adjuvants with DNA vaccine would influence the anti-tumor efficacy of DNA
vaccinations.
Methods:We investigated the effectiveness of α-GalCer and MPL combination as an adjuvant with an HPV-16 E7
DNA vaccine to enhance antitumor immune responses.
Results: By using adjuvant combination for a DNA vaccine, we found that the levels of lymphocyte proliferation,
CTL activity, IFN- γ, IL-4 and IL-12 responses, and tumor protection against TC-1 cells were significantly increased
compared to the DNA vaccine with individual adjuvants.
In addition, inhibition of IL-18 signaling during vaccination decreased IFN-γ responses and tumor protection, and
that this inhibition suggested stimulatory role of IL-18 in adjuvant effects of α-GalCer and MPL combination.
Conclusion: The strong adjuvanticity associated with α-GalCer/MPL combination may to be an important tool in
the development of novel and strong cancer immunotherapy.
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Background
Cervical cancer is the second most common cause of
malignancies in women worldwide, and the oncogenic
activity of the E7 protein that is expressed by high-risk
human papilloma viruses (HPVs), and in particular by
the HPV-16 genotype, has a pivotal role in anogenital
tumors [1, 2].
Several lines of evidence suggest that cell-mediated im-
munity is important in controlling both HPV infection
and HPV-associated neoplasms [3]. Therefore, vaccines
or immunotherapies targeting E7 protein may provide
the opportunity to prevent and treat HPV-associated
malignancies [4, 5].
DNA vaccines can induce both humoral and cellular
immune responses. The clinical benefits of DNA vaccine
are low cost, vaccine stability, high productivity, and easy
modification of antigen in comparison with traditional
protein vaccines. Indeed, DNA vaccines have shown
remarkable success in most animal studies and clinical
trials in humans [6, 7].
However, low immunogenicity has proved a significant
obstacle to efficacy for DNA vaccines, especially in
higher primates and humans [8]. To date, various ap-
proaches have been taken to enhance the potency of
such vaccines [9, 10].
Among the strategies to enhance DNA vaccination,
the use of adjuvant appears to be particularly promising.
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Adjuvants are powerful substances to enhance the im-
munogenicity and boost the protective immunity elicited
by vaccines [11–13]. Toll-like receptors (TLRs) play an
important role in the innate recognition of pathogen-
associated molecular patterns (PAMPs) and initiation of
immune responses in dendritic cells (DCs) [14]. TLR li-
gands have therefore emerged as potential vaccine adju-
vants, particularly in the context of peptide, protein, and
DNA vaccines [4, 15]. Single TLR agonists are currently
being developed and utilized for vaccination and tumor
immunotherapy. Certain combinations of adjuvant mole-
cules could have advantages over use of a single agonist,
as there is evidence that the use of individual TLR ago-
nists in combination with non-TLR agonists may more
efficiently generating or effectively directing immune re-
sponses [16]. Among the TLR agonists, TLR4 agonists
hold particular promise effect as potential vaccine adju-
vants for use in tumors immunotherapy [17]. The first
TLR4 agonist approved for human use as a vaccine adju-
vant is a chemically-modified natural lipid A product de-
rived from the LPS of Salmonella Minnesota R595 and
known as monophosphoryl lipid A (MPL) [18]. MPL is an
effective adjuvant in prophylactic and therapeutic vaccines
and presents an outstanding safety in humans [19, 20].
α-Galactosylceramide (α-GalCer) represents another
group of compounds that has shown to have an strong
effect as vaccine adjuvant for immunotherapy of tumors
[21]. α-GalCer is a glycolipid that has been identified as
a ligand recognized by Va14 natural killer T (iNKT)
cells. A key feature of iNKT cells is the expression of a
single invariant Va14 antigen receptor that recognizes
glycolipid antigens in mice [22]. Several studies have re-
ported that α-GalCer may be used as a systemically de-
livered vaccine adjuvant for the induction of potent
natural killer cell-dependent anti-tumor cytotoxic re-
sponses [23]. α-GalCer enhanced anti-tumor immunity
in mice when administered in combination with various
types of vaccines [10, 24].
It has been shown that the simultaneous induction of
various immune targets by combination of adjuvants
could generate a more effective and longer lasting anti-
tumor immune response; therefore, in the present study
we hypothesized that the combination of NKT cell anti-
gen α-GalCer and MPL may potentiate their antitumor
effects for immunotherapy of cancer. We investigated
the combined adjuvant activity of α-GalCer and MPL for
DNA vaccine-induced protective and antitumor immun-
ity against S.C. TC-1 tumors in C57BL/6 mice.
Methods
Animals
Six to eight week-old female C57BL/6 mice were pur-
chased from the Pasteur Institute (Karaj, Iran) and kept
in the laboratory animal facility of Golestan University
of medical sciences. All animals were fed with enough
food and water to pass adaptation period, and treated
with 6.00 to18.00-hour light/dark cycle. Approved pro-
tocols were applied to all animal experiments with con-
sideration of recommendations for the accurate use
and care of laboratory animals by the ethical commis-
sion of Golestan University.
Adjuvants and blocking antibodies
The iNKT cell ligand α-GalCer was supplied by Enzo
Life Sciences and was solubilized in 150 mM NaCl,
0.5 % Tween 20, referred to as vehicle.
Pure monophosphoryl lipid A (Synthetic lipid A from
E. coli, serotype R515 from Invivogen) as TLR4 agonist
were dissolved in PBS for a final concentration of 1 μg/
ml. The doses used were as follows: 1 μg of GalCer (or
equivalent PBS-diluted vehicle solution) and 25 μg of
MPL per subcutaneous (S.C.) injection.
Blockade of IL-18 was carried out with 100 mg of re-
combinant murine anti-mouse IL-18 clone 93–10 (R&D
Systems) or an isotype matched control.
DNA vaccine preparation
The generation of pcDNA3.1-E7 has been described previ-
ously [25]. Plasmid constructs were confirmed by DNA se-
quencing and expression. Amplification and purification of
DNA were previously described. Stocks of endotoxin free
DNA vaccine plasmids and vector control plasmid
(pcDNA3.1) in 0.1 M PBS were prepared for in-vivo
immunization studies using the EndoFree® Plasmid Maxi
Kit (Qiagen, Hilden, Germany) and dissolved in endotoxin-
free Tris-EDTA (Sigma, St. Louis, MO).
Cell lines and culture medium
TC-1, (part of the Johns Hopkins Special Collection)
was derived from primary epithelial cells of C57BL/6
mice co-transformed with HPV16 E6 and E7 and acti-
vated c-Ha-ras oncogene. TC-1 cell line (HPV-16 E7+)
was used as a tumor model in an H-2b murine system.
The EL4 cells, a mouse lymphoma cell line derived from
C57BL/6- Ly5.2 mice were obtained from the National
Cell Bank of Iran (NCBI, Pasteur Institute, Tehran). TC-
1 and EL4 cell lines were grown in RPMI 1640 (GIBCO,
UK), supplemented with 10 % FBS, 2 mM L-glutamine,
25 mM HEPES, penicillin (100 U/ml), streptomycin
(100 μg/ml) and G418 0.4 mg/ml at 37 °C with 5 % CO2.
In vivo tumor treatment experiment using TC-1 tumor cells
C57BL/6 mice were challenged with 2 × 105 TC-1 tumor
cells/mouse by S.C. injection in the right flank in 0.2 ml
of PBS using a 25G needle for the in vivo tumor treat-
ment experiment.
After 1 week, the C57BL/6 were immunized three times
by S.C. injection of DNA vaccine encoding HPV-16 E7
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(E7 DNA vaccine, 100 μg in 100 μl) with or without adju-
vants of α-GalCer (1 μg), MPL (25 μg) or combinations of
α-GalCer (0.5 μg) and MPL (12.5 μg) thrice at 7-day inter-
vals. As a control, mice were given pcDNA3, PBS, 1 μg α-
GalCer or 25 μg MPL alone.
Subcutaneous tumor volume was estimated according to
Carlsson’s formula [25]. Hence, the largest (a) and the smal-
lest (b) superficial diameters of the tumor were measured
in a blinded, coded fashion twice a week and then the vol-
ume (V) of the tumor was calculated (V = a × b × b/2). The
tumor volume was monitored up to 6 weeks after tumor
challenge.
Statistical analysis was performed using Student’s t test.
All values were expressed as means ± S.D. Three mice
per group were sacrificed 1 week following the third
immunization and the spleens were removed aseptic-
ally, and then cell proliferation, cytolytic activity and
cytokine secretion were assayed. Six mice were also
used for IL-18 blockade experiment.
All tests were performed in triplicate for each mouse. Re-
sults are representative of three independent experiments.
Preparation of splenocytes
Mice were sacrificed and spleens removed using aseptic
technique. Spleens were removed, and the resulting
single-cell suspensions were pelleted, and the red blood
cells were lysed by using a lysis buffer (0.15 M NH4Cl;
1 mM KHCO3; 0.1 mM Na2EDTA; pH 7.2). Cells were
then washed and counted. Splenocytes were resuspended
in RPMI 1640 supplemented with 10 % FBS, 1 % L-glu-
tamine, 1 % HEPES, 0.1 % 2-mercaptoethanol and 0.1 %
penicillin/streptomycin (all from Gibco).
Cytotoxicity assay
One week after last immunization, the mice (three mice
of each group) were sacrificed and their splenocytes
were isolated. For each sample obtained from individual
mice, single-cell suspensions of mononuclear cells (used
as the effector cells) were cultured in RPMI 1640
medium with washed EL4 target cells (a mouse lymph-
oma cell line derived from C57BL/6 (MHC-H2b); ATCC
TIB-39, from the National Cell Bank of Iran (NCBI, Pas-
teur Institute, Tehran)) at various effector-to-target cell
(E/T) ratios (25:1, 50:1, 100:1) and in 96-well flat-bottom
plates for 4 h in phenol red-free RPMI 1640 containing
3 % FBS.
For preparation of the target cells, EL4 cells were stim-
ulated with E7-specific H-2Db CTL epitope at a concen-
tration of 1 μg/ml and then incubated for 4 h. After
centrifugation, the supernatants (50 μl/well) were trans-
ferred into the 96-well flat-bottom plates, and lysis of
target cells were determined by measuring lactate de-
hydrogenase (LDH) release using a LDH cytotoxicity de-
tection kit according to the procedures stated by the
manufacturer (Takara Company, Shiga, Japan). Several
controls were used for the cytotoxicity assay.
The ‘target maximum’ was the total LDH released
from the target cells, and all EL4 cells were lysed by
medium containing 1 % Triton X-100. The ‘target spon-
taneous’ was the natural release of LDH from the target
cells, which was obtained by adding EL4 cells only to the
assay medium. The ‘T cell control’ was used to measure
the natural release of LDH from T cells and was ob-
tained by adding the different ratios of T cells only to
the assay medium.
For all samples, including the controls, the assay was
performed in triplicate. The LDH-mediated conversion of
tetrazolium salt into a red formazan product was mea-
sured at 490 nm after incubation at room temperature for
30 min. The percentage of specific cytolysis was deter-
mined by the following formula:
Cytotoxicity
¼ experimental value − effector spontaneousð Þ − Low control
High control−Low control
 
 100
Lymphocyte proliferation assay
One week after the third immunization, the splenocytes
at a concentration of 2 × 105 cells/well were cultured in
96-well flat-bottom culture plates (NalgeNunc Inter-
national, Denmark) in the presence of E7-specific H-
2Db CTL epitope at a concentration of 1 μg/ml, unspe-
cific mitogen ConA (2 μg/ml) or media at 37 °C for 48 h
in a humidified 5 % CO2 atmosphere.
The preparations were cultured in RPMI 1640 supple-
mented with 10 % FBS. After 48 h of incubation, 10 μg/
ml of MTT [3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltet-
razolium bromide]; (Sigma chemicals) was added to each
well and incubated for 4 h at 37 °C in 5 % CO2. Follow-
ing incubation, the supernatant from each well was re-
moved and formazan crystals were solubilized by adding
100 μl dimethyl sulfoxide into each well.
The absorbance of each well was then determined at a
wavelength of 540 nm, and the results expressed as a
stimulation index (SI). SI was calculated as follows: SI =
OD of stimulated culture/OD of unstimulated culture. All
tests were performed in triplicate for each mouse.
Cytokine secretion assay
One week after the third immunization, mononuclear
cells from spleens of immunized mice at a concentration
of 2 × 106 cells per well were incubated in 24-well plates
for 3 days in phenol red-free RPMI 1640 supplemented
with 10 % FBS, 2 mM L-glutamine, 25 mM HEPES and
0.1 % penicillin/streptomycin, and pulsed with E7-specific
H-2Db CTL epitope at a concentration of 1 μg/ml at 37°
in 5 % CO2.
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The supernatants were collected and assayed for the
presence of IFN- γ, IL-4 and IL-12 using commercially
available sandwich-based ELISA kits (eBioscience, San
Diego, USA) following the manufacturer’s instruction.
All tests were performed in triplicate for each mouse.
Blockade of IL-18
One day prior to all of the vaccinations, Tc-1-treated
mice (n = 3) were injected intra-peritoneally (i.p) with
100 mg of anti-mouse IL-18 clone 93–10 (R&D Systems)
after reconstitution in PBS.
The control groups received an isotype matched IgG
control reconstituted and injected in a similar fashion.
One week following the final blockade and vaccine ad-
ministration (4 weeks post tumor challenge), E7-specific
IFN- γ response was determined (as described in cyto-
kine secretion assay). The tumor volume was also moni-
tored up to 6 weeks after tumor challenge.
Statistical analysis
Lymphocyte proliferation, CTL and cytokine assay were
analyzed by a one-way ANOVA. Significant differences
of tumor growth on given days were assessed by Stu-
dent’s t-test. Differences were considered statistically sig-
nificant when P value < 0.05. All tests were performed in
triplicate and all data are expressed as mean ± SD.
To compare results between the different groups, a
one-way ANOVA was used. The statistical software
SPSS version 16.0 was utilized for statistical analyses.
Differences were considered statistically significant when
p < 0.05.
Results
Cytotoxicity assay
Groups of C57BL/6 mice were immunized three times at
one week intervals with E7 DNA vaccine with or without
adjuvants of α-GalCer, MPL or combinations of α-
GalCer and MPL. Non-radioactive cytotoxicity assay was
performed to estimate the specific CTL cytolysis induced
by various vaccines, in which the re-stimulated spleno-
cytes as the effector cells were incubated with EL4 target
cells pulsed with E7-specific H-2Db CTL epitope. Cyto-
lytic activities are given as the mean percentages of spe-
cific lysis from three mice at effector: target ratio of 50:1
(50:1 E/T), with maximal CD8+ cytotoxic responses to
EL4 target cells.
As shown in Fig. 1, injection of adjuvant alone and
pcDNA3 induced very low antigen-specific CTL re-
sponses. In contrast, immunization with E7 DNA vac-
cine in association with α-GalCer and MPL induced
significant cytolytic effects on target cells as compared
with mice that immunized with the E7 DNA vaccine
alone (P < 0.01). The cytolytic activity from mice vacci-
nated with E7 DNA vaccine plus adjuvant combination
was at least 2 fold higher than those of E7 DNA vaccine
alone. Furthermore, E7 DNA vaccine plus combination
Fig. 1 Legend. Analysis of the cytotoxic activity induced by E7 DNA vaccine plus α-GalCer and MPL combination. CTL activity of the lymphocytes
from immunized mice (three mice per group) was measured at 50:1 E/T ratio by LDH release assay kit as described in Material and Methods section.
Specific lysis of target cells are shown with nonspecific background lysis subtracted. LDH release was expressed as percent cytotoxicity ±
S.D. *** Indicates statistically significant difference between E7 DNA vaccine in combination with α-GalCer and MPL group as determined by
one-way ANOVA (P < 0.001) with other groups. ** shows the statistical significant differences between E7 DNA vaccine plus α-GalCer and E7
DNA vaccine plus MPL treatments than the E7 DNA vaccine alone group (P < 0.01). # shows the statistical significant differences between E7
DNA vaccine plus α-GalCer treatment than the E7 DNA vaccine plus MPL group (P < 0.05)
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of α-GalCer-MPL showed the highest cytotoxic capacity
(69.6 ± 2.3) of all the groups examined (P < 0.001). Not-
ably, T lymphocytes from the mice vaccinated with the
E7 DNA vaccine plus α-GalCer killed 49.2 % ±3.6 of tar-
get cells, which was significantly higher than that of the
cells from E7 DNA vaccine plus MPL injected mice
(37 % ±3.5, P < 0.05).
Lymphocyte proliferation assay
Mice were immunized three times with the indicated
amount of immunogens at one-week intervals: E7 DNA
vaccine, E7 DNA vaccine plus α-GalCer, E7 DNA vac-
cine plus MPL, E7 DNA vaccine plus α-GalCer and
MPL combination, MPL, α-GalCer, pcDNA3, vehicle or
PBS. One week after the third immunization, the spleno-
cytes from the immunized mice were harvested and re-
stimulated in vitro with E7 49–57 for the lymphocyte
proliferation assay.
As shown in Fig. 2, mice immunized with E7 DNA vac-
cine alone had low lymphocyte proliferation response (1.3
± 0.14). In contrast, the in vitro re-stimulation with E749–
57 led to significantly enhanced Ag-specific proliferation
in the splenocytes isolated from mice immunized with E7
DNA vaccine plus α-GalCer and E7 DNA vaccine plus
MPL (P < 0.05). In accordance with the CTL assay,
splenocytes from mice inoculated with DNA vaccine plus
α-GalCer and MPL combination showed evidently the
greatest level of T lymphocyte proliferation upon in vitro
stimulation with the E7 49–57 epitope with a mean SI
value of 3.25 ± 0.19 (P < 0.001). However, there were no
statistically significant differences in Ag-specific lympho-
cyte proliferation between α-GalCer and MPL adjuvanted
groups (P = 0.058). As expected, very little proliferation
was detected from mice immunized with MPL alone, α-
GalCer alone, pcDNA3, vehicle or PBS.
Cytokine secretion assay
In light of the high cellular immune response revealed
by the CTL and lymphocyte proliferation assays, cyto-
kine assay were performed to provide a more holistic
profile of the cellular immunity induced by combination
of α-GalCer and MPL as a DNA vaccine adjuvant. As
shown in Fig. 3a-c, injection of MPL, α-GalCer,
pcDNA3, vehicle or PBS did not induce any significant
antigen-specific IFN- γ, IL-4 and IL-12 secretion. The
production of these cytokines following the E7 DNA
vaccine plus α-GalCer and E7 DNA vaccine plus MPL
was significantly higher than in mice that received the
unadjuvanted DNA vaccine (P < 0.01). Consistent with
the CTL and lymphocyte proliferation assays, mice that
received the DNA vaccine with both α-GalCer and MPL
adjuvants exhibited substantially increased IFN- γ, IL-12
and IL-4 responses as compared with mice that received
the E7 DNA vaccine plus MPL and E7 DNA vaccine plus
α-GalCer (P < 0.01). Meanwhile, mice immunized with
the E7 DNA vaccine plus α-GalCer showed significantly
Fig. 2 Legend. Lymphocyte proliferation levels after in vitro stimulation with HPV-16 E749–57 epitopes. The mice were injected subcutaneously
thrice at 7-day intervals with DNA vaccine plus different adjuvant combinations. One week after final immunization, spleens of individual mice
(three per group) were removed and lymphocyte proliferation was evaluated with MTT method. Values are the mean ± S.D. of the mean for the
experiments. *** Indicates statistically significant difference between the E7 DNA vaccine in combination with α-GalCer and MPL group as
determined by one-way ANOVA (P < 0.001) with other groups. ** shows the statistical significant differences between E7 DNA vaccine plus
α-GalCer and E7 DNA vaccine plus MPL treatments than the E7 DNA vaccine alone group (P < 0.05)
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higher levels of IFN- γ (P < 0.05) and IL-12 (P < 0.01)
than those immunized with the E7 DNA vaccine plus
MPL(P < 0.05); but no significant differences were ob-
served in IL-4 production (P = 0.061). Thus, the immuno-
logical assessments showed that DNA vaccine adjuvanted
with the combination of α-GalCer and MPL resulted in a
synergistic enhancement of DNA vaccine– elicited cellular
immune responses.
In vivo tumor treatment experiment
To investigate whether α-GalCer and MPL adjuvants
could induce regression and therapeutic effect against
preexisting TC-1 tumors in DNA vaccinated mice, E7-
expressing TC-1 tumor cells were injected into C57BL/6
mice at a dose of 2 × 105 TC-1 cells in the right flank.
One week later, C57BL/6 mice were immunized thrice
with the E7 DNA vaccine with or without adjuvants, and
monitored for tumor volume up to 6 weeks after the
tumor challenge.
As shown in Fig. 4, Tumors grew rapidly in mice in-
oculated with MPL, α-GalCer, pcDNA3, vehicle or PBS,
whereas tumor growth was significantly retarded in
mice that received DNA vaccine expressing E7 protein
with or without adjuvants. The average tumor volume in
the adjuvanted DNA vaccine and unadjuvanted DNA vac-
cine groups was significantly lower than that in the MPL,
α-GalCer, pcDNA3, vehicle or PBS groups (P < 0.001).
The statistical analysis of average tumor volumes exhib-
ited significant difference between adjuvanted DNA vac-
cine groups and E7 DNA group (P < 0.001). At 21 and
28 days after vaccination, the average tumor volumes of
the E7 DNA vaccine plus α-GalCer and MPL combination
animals were significantly less (P < 0.01) than in those vac-
cinated with the E7 DNA vaccine plus α-GalCer and E7
DNA vaccine plus MPL groups. Furthermore, significant
difference in average tumor volumes was detected be-
tween the E7 DNA vaccine plus α-GalCer -treated animals
versus those treated with the E7 DNA vaccine plus MPL
(P < 0.05). Similar results were obtained in three inde-
pendent experiments with six mice per group.
Effect of IL-18 blockade on Ag- specific IFN- γ secretion
To determine whether blockade of IL-18 signaling dur-
ing DNA vaccine plus α-GalCer and MPL immunization
could also induce a greater IFN- γ response, C57BL/6
mice were vaccinated as before with concomitant ad-
ministration of anti-IL-18 mAb or isotype control mAb
1 day prior to all of the vaccinations and for 3 weeks.
One week following the final blockade and vaccine
administration (4 weeks post tumor challenge), we deter-
mined the E7-specific IFN- γ response (Fig. 5). No
significant increase in the levels of IFN-γ from E7-
restimulated splenocytes was observed following DNA
vaccination of C57BL/6 mice in the presence of anti-IL-18
Fig. 3 Legend. Concentration of IFN- γ (a), IL-12 (b) and IL-4 (c) in
supernatant following stimulation of cultured splenocytes with
E749–57 epitopes. Data presented as means ± S.D. for three mice
per group. *** Indicates statistically significant difference (P < 0.001)
between E7 DNA vaccine in combination with α-GalCer and MPL
group as determined by one-way ANOVA (P < 0.001) with other
groups (a, b, c). ** shows the statistical significant differences
between E7 DNA vaccine plus α-GalCer and E7 DNA vaccine plus
MPL treatments than the E7 DNA vaccine alone group (P < 0.01). a,
b # (P < 0.05) and ## (P < 0.001) shows the statistical significant
differences between E7 DNA vaccine plus α-GalCer treatment than
the E7 DNA vaccine plus MPL group
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mAbs, as compared to DNA vaccination in the presence
of isotype control mAbs. However, mice immunized with
E7 DNA vaccine plus α-GalCer and MPL combination in
the presence of anti-IL-18 showed significant reduction in
E7-specific IFN-γ response over E7 DNA vaccine plus α-
GalCer and MPL combination group in the presence of
isotype control mAbs (P < 0.001). Furthermore, E7 DNA
vaccine combined with individual adjuvants in the pres-
ence of anti-IL-18 did not exhibit significant E7-specific
IFN- γ decrease over mice immunized with E7 DNA vac-
cine combined with individual adjuvants in the presence
of isotype control mAbs.
These data suggest that blockade of IL-18 during E7
DNA vaccine in combination with α-GalCer and MPL
reduces IFN- γ secretion than E7 DNA vaccine com-
bined with individual adjuvants.
Effect of IL-18 blockade on therapeutic effect against TC-1
tumor
We determined whether abrogation of IL-18 signaling dur-
ing DNA vaccine plus α-GalCer and MPL immunization
only would lead to reduced therapeutic effect against TC-1
tumor. This would show whether IL-18 has a regulatory
role specifically at the level of initial DNA vaccination, as
has been shown in other immunization models (38–42).
To do this we administered anti-mouse IL-18 mAb, or iso-
type control mAb, to C57BL/6 mice during vaccination,
one day prior to all of the vaccinations, for 3 weeks and
the tumor volume was monitored up to 6 weeks after the
tumor challenge.
One week after last treatment, although E7 DNA vac-
cine plus α-GalCer and MPL combination mice in the
presence of isotype control had significantly greater
protection compared to DNA vaccination in the pres-
ence of isotype control mAbs, there was no additional
tumor volume growth observed in E7 DNA vaccine
plus α-GalCer and MPL combination mice in the pres-
ence of anti-IL-18 mAbs (data not shown). However by
week 4, E7 DNA vaccine plus α-GalCer and MPL com-
bination mice in the presence of anti-IL-18 mAbs
showed an increase in tumor volume over E7 DNA vac-
cine plus α-GalCer and MPL combination in the pres-
ence of isotype control (Fig. 6). Additionally, mice
immunized with E7 DNA vaccine combined with indi-
vidual adjuvants in the presence of isotype control mice
did not reveal further protection against tumor over E7
DNA vaccine combined with individual adjuvants in
the presence of anti-IL-18 mAbs. These data suggest
that blockade of IL-18 at the time of administering E7
DNA vaccine plus α-GalCer and MPL combination de-
creases the vaccine-driven antitumor response against
TC-1 tumor as compared with other treatments.
Discussion
The uses of adjuvants and relevant antigen targets in
vaccine development have been an important focus of
Fig. 4 Legend. In vivo antitumor effects generated by treatment with E7 DNA vaccine plus α-GalCer, E7 DNA vaccine plus MPL, E7 DNA vaccine
plus α-GalCer and MPL combination. C57BL/6 mice were inoculated with 2 × 105 TC-1 tumor cells subcutaneously. Mice were then treated with
DNA vaccine plus different adjuvant combinations as described in Materials and Methods. Mice were monitored for tumor growth by measuring
diameters with calipers twice a week. Line and scatter plot graphs depicting the tumor volume (in mm3) are presented. The data presented are a
representation of three independent experiments
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improving vaccine responses. The growing number of
adjuvants can be used individually or in combination to
maximize effects. However, there have been few reports
addressing the potential use of adjuvants together with
DNA vaccines. In this study, we examine the use of α-
GalCer and MPL as a combined adjuvant for HPV-16
E7 DNA-based vaccination strategy. The results dem-
onstrated that HPV-16 E7 DNA-induced E7-specific
cellular immune responses and protection of animals
from HPV 16 E7-associated tumor growth can be en-
hanced with α-GalCer and MPL adjuvant combination,
as evidenced by significant enhanced lymphocyte prolif-
eration, IFN-γ, Il-12, IL-4, cytotoxicity and in vivo anti-
tumor effects, compared with control groups. However,
injection with either E7 or individual adjuvants failed
to show significant protection from tumor growth.
These suggest that both E7 and α-GalCer -MPL adju-
vant combination are required for therapeutic vaccine
efficacies in this tumor model system.
It has been shown that that administration of iNKT
cell ligands induces phenotypic and functional matur-
ation of DCs leading to the priming of CD4 and CD8
effector T cells to antigens in mice. Furthermore, α-
GalCer can stimulate NK activity and cytokine produc-
tion by NKT cells and exhibits potent cytolytic activity
in vivo [26]. Invariant Natural killer T cell (iNKT cells)
are a subset of T cells that recognize glycolipid α-GalCer
antigen bound by the major histocompatibility complex
(MHC)-class-I-related protein CD1d, a non-polymorphic
non-classical MHC class I molecule [27].
In agreement with our antitumor findings, it has been
stated that administration of α-GalCer with DNA vaccines
showed adjuvant effects against tumors. A DNA vaccine
expressing HPV-16 E7 in combination with α-GalCer in-
duced a significant E7-specific CD8 + T cell response in
immunized mice through stimulating maturation of DCs.
In fact, priming with a DNA vaccine in the presence of α-
GalCer and boosting with E7-pulsed DC led to a signifi-
cant enhancement of E7-specific CD8(+) effector and
memory T-cells as well as significantly improved thera-
peutic effects against an E7-expressing tumor model (TC-
1) in vaccinated mice [28]. It was also demonstrated that
α-GalCer had adjuvant activity on HIV-1 DNA vaccines
after administration at priming, leading to the enhance-
ment of both antigen-specific cellular and humoral re-
sponses [29]. Guillonneau et al. demonstrated that giving
alpha-GalCer with an inactivated influenza A virus sub-
cutaneously improved protective efficacy of inactivated
influenza A virus (IAV) [30].
α-GalCer has also been shown to enhance the anti-
tumor activity in mice when administered in combination
with various types of vaccines [9, 31–33]. Choi el al
showed that treatment of the transgenic mice with ovarian
tumor cell-based vaccines combined with adjuvant α-
GalCer led to prolonged survival as well as increased
numbers of tumor-specific CD8+ T cells [34]. Therefore,
α-GalCer represents an important adjuvant for improving
the efficacy of tumor cell-based vaccines to treat ovarian
cancer.
Although the adjuvant properties of α-GalCer have been
demonstrated in many vaccine animal models. However,
limitations of single-adjuvant vaccine formulations are
driving the need to explore combination adjuvants. For
this reason investigators are exploring the potential of
using formulations with multiple adjuvants in a vaccine.
Several adjuvant combinations have been tested. Some
adjuvant combinations even show a synergistic response
following the co-administration of adjuvants: the effect of
the two adjuvants combined is more beneficial than the
sum of the effect of each adjuvant [35].
Because the DCs maturation after presentation of α-
GalCer to NKT cells seems to operate independently of
TLR adaptor protein MyD88 [26], therefore recent stud-
ies have highlighted the potential for synergizing the in-
teractions between TLR ligands and iNKT cell activation
in the design of effective vaccine adjuvants.
Fig. 5 Legend. Anti-IL-18 blockade of TC-1-transplanted C57BL/6
mice during E7 DNA vaccination in combination with α-GalCer and
MPL reduced the IFN- γ secretion. One week following the final
blockade and vaccine administration, splenocytes were isolated and
restimulated with E749–57 epitopes as described in Materials and
Methods. The production of IFN- γ was measured from the supernatants
of these restimulations by ELISA. Data are representative of three
separate experiments. Data presented as means ± S.D. for three
mice per group. Treatment groups were compared to the control
group using one-way ANOVA. *** Indicates statistically significant
difference (P < 0.001) between E7 DNA vaccine plus α-GalCer and
MPL combination mice in the presence of anti-IL-18 mAbs over E7
DNA vaccine plus α-GalCer and MPL combination in the presence
of isotype control
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Hermans et al. provided evidence for cooperation be-
tween the adjuvant activities of α-GalCer and MPL,
which binds with TLR4. It was showed that the simul-
taneous administration of iNKT cell ligand α-GalCer and
MPL had a synergistic effect on the induction of CD8+
T-cell and antibody responses to OVA in wild-type ani-
mals compared with animals treated with the ligands
individually. Antigen-specific CD8(+) T cell responses
induced in the presence of the α-GalCer and MPL
showed improved effector and proliferation function,
than those induced with either ligand alone[36], the
findings are in agreement with our current results. In
another study, it was described that DC maturation in-
duced by a TLR ligand was also enhanced by iNKT cell
activity. Exposure of APCs to both TLR-mediated and
iNKT cell–mediated signals stimulated significantly
greater DC-induced T-cell immunity than exposure to
either stimulus alone [33].
To understand whether IL-18 blockage following DNA
vaccine plus α-GalCer-MPL combination limited vaccine
efficacy in terms of the IFN- γ generated, and most im-
portantly whether this would limit therapeutic effects
against TC-1 tumor, C57BL/6 mice were administrated
with anti-mouse IL-18 Ab, or isotype control mAb,
1 day prior to all of the vaccinations, and subsequently
analyzed by the IFN-γ secretion and tumor volume.
We found that blockade of IL-18 signaling in E7 DNA
vaccine plus α-GalCer and MPL combination mice re-
duced E7-specific IFN-γ, and that this treatment de-
creased the protection against tumor growth compared
with isotype control mAb.
Our findings are in agreement with previously pub-
lished studies demonstrating stimulatory role of IL-18 in
the antitumor immune response via induction of IFN- γ
production from NK and CD4+ T cells [37].
IL-18, IFN- γ-inducing factor, acts synergistically with
IL-12 in inducing IFN- γ synthesis by a NKT and NK
cells to kill target cells in a Fas ligand-dependent manner
[38]. IFN- γ has a significant role in enhancing cell-
mediated antitumor immunity by increasing tumor im-
munogenicity through enhancing antigen presentation
as well as prompting antigen-presenting cells, NK cells,
CTLs and Th1 T cells [39].
Furthermore, several studies have shown the antitu-
mor efficacy of IL-18 in animal tumor models. For
example, IL-18 exerted antitumor immunity by acti-
vating NK cells and establishing cytotoxic CD4+ T
cells [37]. In support of the latter possibility, blockade
of IL-18 presented marked reduction in IFN-γ pro-
duction after HPV-16 E7 re-stimulation. In addition,
absence of the cytokine led to worsening of tumor
growth.
Fig. 6 Legend. Anti-IL-18 mAb treatment during DNA vaccination decreases therapeutic effects against TC-1 tumor in C57BL/6 mice. One day
prior to all of the vaccinations, Tc-1-treated mice (n = 3) were injected intra-peritoneally (i.p) with 100 mg of anti-mouse IL-18 or isotype control
mAb. One week following the final blockade and vaccine administration, the tumor volume was monitored up to 6 weeks after the tumor challenge.
Line and scatter plot graphs depicting the tumor volume (in mm3) are presented. The data presented are a representation of three independent
experiments. Bar graph (Mean ± SD) showing average tumor volume on the day of 28. *** Indicates statistically significant difference (P < 0.001)
between E7 DNA vaccine plus α-GalCer and MPL combination mice in the presence of anti-IL-18 mAbs over E7 DNA vaccine plus α-GalCer and MPL
combination in the presence of isotype control
Gableh et al. Journal of Biomedical Science  (2016) 23:16 Page 9 of 11
Conclusions
Taken together, our study shows that co-administration
α-GalCer and MPL with E7 DNA could significantly re-
duce tumor volume and eradicate the established E7-
expressing tumors. The combination adjuvants might be
able to employ low doses of iNKT cell antigens, thus
avoiding some of the obstacles associated with vaccines
that require high doses of iNKT cell antigens. Addition-
ally, the rational combination of the adjuvants is likely to
offer opportunities for the development of therapeutic
vaccines for therapy of cervical cancer.
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